Antisense compounds, compositions and methods are provided for modulating the expression of IL-1 receptor-associated kinase-4. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding IL-1 receptor-associated kinase-4. Methods of using these compounds for modulation of IL-1 receptor-associated kinase-4 expression and for treatment of diseases associated with expression of IL-1 receptor-associated kinase-4 are provided.
Claims What is claimed is: 1. A compound 8 to 50 nucleobases in length targeted to nucleobases 31 through 50 of a start codon region, nucleobases 62 through 81, nucleobases 85 through 113, nucleobases 122 through 141, nucleobases 149 through 168, nucleobases 180 through 199, nucleobases 238 through 257, nucleobases 260 through 289, nucleobases 371 through 390, nucleobases 394 through 413, nucleobases 426 through 459, nucleobases 639 through 658, nucleobases 683 through 722, nucleobases 777 through 796, nucleobases 800 through 819, nucleobases 841 through 860, nucleobases 391 through 910, nucleobases 914 through 985, nucleobases 1081 through 1105, nucleobases 1190 through 1209, nucleobases 1220 through 1247, of a coding region, nucleobases 1548 through 1579, nucleobases 1646 through 1693, nucleobases 1720 through 1775, nucleobases 1810 through 1873, nucleobases 1894 through 1913, nucleobases 1951 through 1970, nucleobases 1985 through 2004, nucleobases 2066 through 2085, nucleobases 2089 through 2108, nucleobases 2137 through 2176, nucleobases 2211 through 2286, nucleobases 2377 through 2396, nucleobases 2419 through 2438, or nucleobases 2469 through 2488 of a 3'-untranslated region of a nucleic acid molecule encoding IL-1 receptor-associated kinase-4 of SEQ ID NO: 3 wherein said compound specifically hybridizes with one of said regions and inhibits the expression of IL-1 receptor-associated kinase-4. 2. The compound of claim 1 which is an antisense oligonucleotide. 3. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage. 4. The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage. 5. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 6. The compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety. 7. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 8. The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine. 9. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 10. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 11. The composition of claim 10 further comprising a colloidal dispersion system. 12. The composition of claim 10 wherein the compound is an antisense oligonucleotide. 13. A method of inhibiting the expression of IL-1 receptor-associated kinase-4 in cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 1 so that expression of IL-1 receptor-associated kinase-4 is inhibited. 